Supplemental Guarantor Financial Information Condensed Consolidating Statement of Cash Flows (Detail) (USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | $24,932 | $24,093 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 66,539 | 67,584 |
Equity-based compensation expense | 9,201 | 7,758 |
Asset Impairment Charges | 5,149 | 0 |
Deferred tax expense (benefit) | 12,895 | -9,678 |
Employee benefit plans | 1,603 | 7,801 |
Amortization of Financing Costs and Discounts | 5,864 | 4,490 |
Gain (Loss) on Disposition of Assets | 747 | 35 |
Changes in working capital, net | -13,190 | 47 |
Change in taxes receivable, net | 7,894 | 12,448 |
Excess tax benefits from equity share-based payment arrangements | 1,508 | 0 |
Change in non-current accrued taxes | 149 | -10,535 |
Funding of qualified pension plans | -15,957 | -12,611 |
Other Operating Activities, Cash Flow Statement | -2,387 | 108 |
Net cash provided by operating activities | 101,931 | 91,540 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 70,000 | -69,000 |
Additions to plant and equipment | -54,029 | -54,400 |
Proceeds from Sale of Productive Assets | 733 | 0 |
Net cash used for investing activities | 16,704 | -123,400 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Proceeds from Issuance of Long-term Debt | 300,000 | 275,000 |
Repayment of Cellu Tissue debt | -375,000 | -150,000 |
Payments for Repurchase of Common Stock | -100,000 | -75,783 |
Investment (to) from Parent | 0 | 0 |
Proceeds from (Repayments of) Short-term Debt | 47,047 | 0 |
Payments of Debt Issuance Costs | -2,995 | -4,834 |
Payment of tax withholdings on equity-based payment arrangements | -792 | -4,173 |
Excess Tax Benefit from Share-based Compensation, Financing Activities | 1,508 | 0 |
Other, net | 1,500 | 0 |
Net cash (used for) provided by financing activities | -128,732 | 40,210 |
Increase in cash | -10,097 | 8,350 |
Cash at beginning of period | 23,675 | 12,579 |
Cash at end of period | 13,578 | 20,929 |
Issuer | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | 19,343 | 17,839 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 43,388 | 40,337 |
Equity-based compensation expense | 9,201 | 7,758 |
Asset Impairment Charges | 0 | ' |
Deferred tax expense (benefit) | 31,563 | -776 |
Employee benefit plans | 1,603 | 7,801 |
Amortization of Financing Costs and Discounts | 5,864 | 4,490 |
Gain (Loss) on Disposition of Assets | 462 | 0 |
Changes in working capital, net | -15,079 | -7,488 |
Change in taxes receivable, net | 2,493 | 11,643 |
Excess tax benefits from equity share-based payment arrangements | 1,508 | ' |
Change in non-current accrued taxes | 220 | -10,558 |
Funding of qualified pension plans | -15,957 | -12,611 |
Other Operating Activities, Cash Flow Statement | -1,947 | 209 |
Net cash provided by operating activities | 79,646 | 58,644 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 70,000 | -69,000 |
Additions to plant and equipment | -42,478 | -40,598 |
Proceeds from Sale of Productive Assets | 38 | ' |
Net cash used for investing activities | 27,560 | -109,598 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Proceeds from Issuance of Long-term Debt | 300,000 | 275,000 |
Repayment of Cellu Tissue debt | -375,000 | -150,000 |
Payments for Repurchase of Common Stock | -100,000 | -75,783 |
Investment (to) from Parent | 14,482 | 19,039 |
Proceeds from (Repayments of) Short-term Debt | 47,047 | ' |
Payments of Debt Issuance Costs | -2,995 | -4,834 |
Payment of tax withholdings on equity-based payment arrangements | -792 | -4,173 |
Excess Tax Benefit from Share-based Compensation, Financing Activities | 1,508 | ' |
Other, net | 1,500 | ' |
Net cash (used for) provided by financing activities | -114,250 | 59,249 |
Increase in cash | -7,044 | 8,295 |
Cash at beginning of period | 18,273 | 11,105 |
Cash at end of period | 11,229 | 19,400 |
Guarantor Subsidiaries | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | -14,871 | -9,028 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 21,416 | 25,590 |
Equity-based compensation expense | 0 | 0 |
Asset Impairment Charges | 5,149 | ' |
Deferred tax expense (benefit) | -6,516 | -11,231 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 285 | 34 |
Changes in working capital, net | 4,464 | 5,748 |
Change in taxes receivable, net | -12,730 | 9,153 |
Excess tax benefits from equity share-based payment arrangements | 0 | ' |
Change in non-current accrued taxes | -60 | 19 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | -440 | -101 |
Net cash provided by operating activities | -3,303 | 20,184 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | -11,330 | -11,854 |
Proceeds from Sale of Productive Assets | 695 | ' |
Net cash used for investing activities | -10,635 | -11,854 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Proceeds from Issuance of Long-term Debt | 0 | 0 |
Repayment of Cellu Tissue debt | 0 | 0 |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | 13,938 | -8,334 |
Proceeds from (Repayments of) Short-term Debt | 0 | ' |
Payments of Debt Issuance Costs | 0 | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Excess Tax Benefit from Share-based Compensation, Financing Activities | 0 | ' |
Other, net | 0 | ' |
Net cash (used for) provided by financing activities | 13,938 | -8,334 |
Increase in cash | 0 | -4 |
Cash at beginning of period | 0 | 5 |
Cash at end of period | 0 | 1 |
Non-Guarantor Subsidiaries | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | 1,002 | -89 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 1,735 | 1,657 |
Equity-based compensation expense | 0 | 0 |
Asset Impairment Charges | 0 | ' |
Deferred tax expense (benefit) | -32 | -472 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 0 | 1 |
Changes in working capital, net | -2,575 | 1,787 |
Change in taxes receivable, net | 99 | -83 |
Excess tax benefits from equity share-based payment arrangements | 0 | ' |
Change in non-current accrued taxes | -11 | 4 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | 0 | 0 |
Net cash provided by operating activities | 218 | 2,805 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | -221 | -1,948 |
Proceeds from Sale of Productive Assets | 0 | ' |
Net cash used for investing activities | -221 | -1,948 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Proceeds from Issuance of Long-term Debt | 0 | 0 |
Repayment of Cellu Tissue debt | 0 | 0 |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | -3,050 | -798 |
Proceeds from (Repayments of) Short-term Debt | 0 | ' |
Payments of Debt Issuance Costs | 0 | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Excess Tax Benefit from Share-based Compensation, Financing Activities | 0 | ' |
Other, net | 0 | ' |
Net cash (used for) provided by financing activities | -3,050 | -798 |
Increase in cash | -3,053 | 59 |
Cash at beginning of period | 5,402 | 1,469 |
Cash at end of period | 2,349 | 1,528 |
Eliminations | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | 19,458 | 15,371 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 0 | 0 |
Equity-based compensation expense | 0 | 0 |
Asset Impairment Charges | 0 | ' |
Deferred tax expense (benefit) | -12,120 | 2,801 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 0 | 0 |
Changes in working capital, net | 0 | 0 |
Change in taxes receivable, net | 18,032 | -8,265 |
Excess tax benefits from equity share-based payment arrangements | 0 | ' |
Change in non-current accrued taxes | 0 | 0 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | 0 | 0 |
Net cash provided by operating activities | 25,370 | 9,907 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | 0 | 0 |
Proceeds from Sale of Productive Assets | 0 | ' |
Net cash used for investing activities | 0 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Proceeds from Issuance of Long-term Debt | 0 | 0 |
Repayment of Cellu Tissue debt | 0 | 0 |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | -25,370 | -9,907 |
Proceeds from (Repayments of) Short-term Debt | 0 | ' |
Payments of Debt Issuance Costs | 0 | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Excess Tax Benefit from Share-based Compensation, Financing Activities | 0 | ' |
Other, net | 0 | ' |
Net cash (used for) provided by financing activities | -25,370 | -9,907 |
Increase in cash | 0 | 0 |
Cash at beginning of period | 0 | 0 |
Cash at end of period | $0 | $0 |